Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodiesSaathvik R. Kannan, Kamal Singh, Siddappa N. Byrareddy et al.|Journal of Autoimmunity|2021Cited by 234
Potential therapeutic targets for Mpox: the evidence to dateSiddappa N. Byrareddy, Kamal Singh, Kalicharan Sharma et al.|Expert Opinion on Therapeutic Targets|2023Cited by 20